In adults with cirrhosis and type 2 diabetes, glucagon-like peptide-1 receptor agonist therapy significantly lowered the risk for death and other adverse outcomes, a study found.
TOPLINE: Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use lowers the risk for death, cardiovascular disease, decompensated cirrhosis, and liver failure in adults with type 2 diabetes (T2D) and compensated liver cirrhosis, new observational data show. METHODOLOGY: Population-based cohort study using data from the National Health Insurance Research Database of Taiwan. Propensity-score matching was used to construct 467 matched pairs of GLP-1 RA users and nonusers (mean age, 57) with T2D and compensated liver cirrhosis. All-cause mortality, cardiovascular events, decompensated cirrhosis, and other key outcomes were compared using multivariable-adjusted Cox proportional hazards models. TAKEAWAY: During mean follow-up of about 3 years,…